Search

everythinglearnresearchcommunity

for

Search:↓

Verteporfin might reverse severe hair loss but is still in early testing stages. It could be a future option for NW6-7, though expensive.

A user has been using sublingual minoxidil for hair loss due to difficulty obtaining pills and is concerned about cancer risk from ethanol exposure. Other users advise against this method, suggesting topical application instead, and debate the potential risks of ingesting topical minoxidil.

The user experienced side effects from daily finasteride and reduced the dosage to 0.25mg twice a week while continuing minoxidil. They are considering topical anti-androgens but are concerned about application difficulties and potential side effects.

Salicylic Acid shampoo may hinder topical minoxidil but not oral minoxidil, which works through the liver. The user plans to continue using oral minoxidil and is concerned about the shampoo's effect on it.

Pyrilutamide is being discussed as an alternative for those who can't use finasteride, but users report it may be ineffective at low concentrations. Some users are combining it with minoxidil, microneedling, and other treatments, but results vary.

The conversation discusses the potential benefits of creating a hydrophobic version of finasteride to reduce systemic side effects while maintaining scalp health. It compares this idea to fluridil, which is designed to be hydrophobic and has less systemic absorption.

Rapamycin and metformin may have hair regeneration properties. Specific treatments discussed include Minoxidil, finasteride, and RU58841.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

A poem humorously suggests hope for a new hair loss treatment, PP405, while users debate the effectiveness and side effects of current treatments like Finasteride. Concerns are raised about Finasteride's side effects, especially for young users, and skepticism about new treatments is expressed.

Painkillers like Aspirin may reduce Minoxidil's effectiveness by inhibiting the enzyme PGHS-1, which is crucial for hair growth. Using NSAIDs that inhibit COX-2 or combining Minoxidil with PGF2/E2 analogues or retinoids may enhance its efficacy.

A user suggests that a .25% topical finasteride solution could reduce scalp DHT levels without affecting bloodstream DHT levels, potentially avoiding sexual side effects. They question why a 2.5% solution was chosen and if a custom .25% solution can be ordered.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

The user halted hair loss using 0.01% topical liposomal finasteride daily, with no side effects or regrowth, and recently added 5% minoxidil and low-level laser therapy. They recommend this conservative approach for those hesitant about finasteride.

VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

Minoxidil may age skin by slowing collagen synthesis, but using collagen peptides and a basic skincare routine might counteract this. Foam minoxidil could reduce systemic absorption and avoid alcohol-related side effects.

A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.

The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.

The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.

The conversation discusses a user experimenting with RU58841 for hair regrowth by ingesting it, which others find concerning. There are mentions of potential side effects and comparisons to other treatments like minoxidil, finasteride, and flutamide.

The user is experiencing scalp irritation from a compounded treatment of finasteride, minoxidil, and tretinoin. They are considering switching to a non-alcohol, propylene glycol-free formula with a lower tretinoin percentage to reduce irritation.

The conversation discusses combining oral dutasteride with topical finasteride to further reduce scalp DHT levels for hair regrowth. Users debate the effectiveness and safety of this combination, with some suggesting alternatives like topical antiandrogens such as RU58841, fluridil, and alfatradiol.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

The user has been using finasteride, minoxidil, and ketoconazole for hair loss, showing good progress without significant side effects. They plan to have a hair transplant in March and hope to eventually stop using oral minoxidil.

Topical Metformin shows potential for regenerating hair follicles and minimizing scarring in hair transplant donor areas, similar to Verteporfin but without its side effects. The discussion suggests considering Metformin for post-hair transplant care, though more human trials are needed.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

Latanoprost is discussed as a potential hair loss treatment, noted for its synergy with minoxidil and 5-AR inhibitors, but concerns include its effectiveness on scalp hair, cost, and potential skin darkening. Some users express interest in trying latanoprost or bimatoprost despite limited real-world evidence.